Discovery of Juglone Derivatives as Novel STAT3 Inhibitors with Potent Suppression of Cancer Cell Stemness against Breast Cancer
Journal of Medicinal Chemistry · 24.07.2025 · 68 (14) · 15085-15109
DOI: 10.1021/acs.jmedchem.5c01301 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, online erschienen am 10.07.2025. Verfasst von Zejun Zhang und 5 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Natural Medicines, China Pharmaceutical University, No. 639 Longmian Dadao, Nanjing 211198, China. Hauptthemen laut MEDLINE: STAT3 Transcription Factor, Naphthoquinones, Breast Neoplasms, Neoplastic Stem Cells. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 47 Literaturangaben. Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Breast cancer stem cells (BCSCs) are pivotal in tumor initiation, progression, and therapeutic resistance, underscoring the need for targeted interventions. Signal transducer and activator of transcription 3 (STAT3) has been implicated in maintaining cancer stemness, representing a compelling therapeutic target. Here, we describe the structure-guided optimization of Juglone, yielding novel STAT3 inhibitors with improved potency. The representative compound 35 (YZ-35) demonstrated potent STAT3 phosphorylation and exhibited nanomolar affinity in binding assays (IC50 = 190 nM). YZ-35 exhibited remarkable antiproliferative activity across multiple breast cancer cell lines and selectively suppressed BCSC self-renewal, outperforming TTI-101 and matching BBI-608 in potency. In vivo, YZ-35 achieved approximately 90% tumor growth inhibition (10 mg/kg) in xenograft models, with reduced toxicity versus paclitaxel. Mechanistic studies confirmed STAT3 pathway disruption and BCSC depletion. These results highlight YZ-35 as a natural product-derived STAT3 inhibitor with dual antitumor and anti-CSC activity, offering a translational strategy for refractory BRCA.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- State Key Laboratory of Natural Medicines, China Pharmaceutical University, No. 639 Longmian Dadao, Nanjing 211198, China.
- School of Life Science and Technology, China Pharmaceutical University, No. 639 Longmian Dadao, Nanjing 211198, China.
- Department of General Surgery, Colorectal Institute of Nanjing Medical University, The First Affiliated Hospital of Nanjing Medical University, 300 Guangzhou Road, Nanjing 210000, China.
ORCID-Profile: Wenying Yu
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Zhang, Z., Liao, Y., Zhang, J., Li, Q., Feng, Y., & Yu, W. (2025). Discovery of Juglone Derivatives as Novel STAT3 Inhibitors with Potent Suppression of Cancer Cell Stemness against Breast Cancer. Journal of Medicinal Chemistry, 68(14), 15085-15109. https://doi.org/10.1021/acs.jmedchem.5c01301
Vancouver
Zhang Z, Liao Y, Zhang J, Li Q, Feng Y, Yu W. Discovery of Juglone Derivatives as Novel STAT3 Inhibitors with Potent Suppression of Cancer Cell Stemness against Breast Cancer. Journal of Medicinal Chemistry. 2025;68(14):15085-15109. doi:10.1021/acs.jmedchem.5c01301
BibTeX
@article{Zhang2025,
author = {Zhang, Zejun and Liao, Yixian and Zhang, Jiaxing and Li, Qingyuan and Feng, Yifei and Yu, Wenying},
title = {Discovery of Juglone Derivatives as Novel STAT3 Inhibitors with Potent Suppression of Cancer Cell Stemness against Breast Cancer},
journal = {Journal of Medicinal Chemistry},
year = {2025},
volume = {68},
number = {14},
pages = {15085--15109},
doi = {10.1021/acs.jmedchem.5c01301}
}
EUVIMED